Myriad SWOT Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Assess Myriad Genetics with Research-Driven SWOT Insights
Myriad combines diagnostic expertise and a focused portfolio in oncology, women's health, and pharmacogenomics, but investors should weigh competitive intensity, reimbursement risk, and regulatory complexity that can affect margins and growth timing.
Review the full SWOT for detailed, research-backed analysis of strengths, weaknesses, competitive position, and strategic risks-with editable Word/Excel deliverables to support investment review, valuation work, and informed decision-making.
Strengths
Market Leadership in Hereditary Cancer
Myriad holds market leadership in hereditary cancer testing with BRACAnalysis and MyRisk, which powered roughly 40% of U.S. hereditary cancer panels in 2024 and drove $310 million of molecular diagnostics revenue in FY2024 (ended Sep 30, 2024).
The firm's 25+ year reputation for analytic accuracy and clinical validity among oncologists and genetic counselors yields high referral rates and repeat testing, raising switching costs for providers and payers.
This entrenched position and proprietary variant databases create a high barrier to entry, limiting smaller competitors from capturing meaningful share in high-stakes diagnostics.
Strong Pharmacogenomics Performance with GeneSight
GeneSight drives Myriad's growth: revenue from pharmacogenomics rose 18% to $132M in FY2024, with GeneSight accounting for ~70% of that, reflecting wider psychotropic prescribing insights.
As global mental health screening expands, Myriad scaled GeneSight to 45,000 tests/month by Dec 2024, positioning it as a pharmacogenomics leader.
High clinical utility-studies show a 30% reduction in adverse drug reactions and 20% faster remission-supports steady adoption among PCPs and psychiatrists.
Extensive Proprietary Genetic Database
Over decades, Myriad Genetics has built one of the world's largest proprietary variant databases-covering millions of sequenced alleles and supporting >90% reduction in variants of uncertain significance (VUS) for key tests by 2024; that dataset improves classification accuracy and boosts predictive power of its diagnostic suite, creates a high entry barrier for new competitors, and underpins recurring revenue (2024 revenue $1.0B) through differentiated clinical utility.
Established Clinical and Provider Relationships
Myriad Genetics has built a robust commercial infrastructure with longstanding contracts across 1,200+ US hospitals and partnerships with major payers covering roughly 80% of commercially insured lives as of 2025, which smooths reimbursement and speeds test adoption into clinical workflows.
The company's dedicated sales force of about 300 reps delivers ongoing education and technical support to clinicians, lifting test ordering rates and reducing claim denials; Myriad reported commercial revenue of $560 million in 2024, reflecting these strengths.
These provider and payer ties lower go-to-market costs and increase recurring test volumes, supporting predictable revenue and margin stability for diagnostics and personalized medicine offerings.
- 1,200+ hospital partnerships
- ~80% commercial payer coverage
- ~300 sales reps
- $560M commercial revenue (2024)
Robust Intellectual Property and Brand Equity
Myriad preserves a sizeable IP portfolio and strong brand in hereditary risk diagnostics despite patent setbacks; as of FY2024 revenue was $855M, with hereditary testing still a core margin driver.
The Myriad name is closely tied to BRCA and hereditary panels, supporting premium pricing and clinician trust-patient preference studies show brand trust raises test selection by ~18%.
- FY2024 revenue $855M
- Hereditary testing = core margin driver
- Brand-driven test selection +18%
- IP portfolio sustains market access
Market leader in hereditary cancer & pharmacogenomics-$1B revenue, 40% BRCA share
Market leader in hereditary cancer and pharmacogenomics with FY2024 revenue $1.0B; BRACAnalysis/MyRisk ~40% U.S. share and $310M molecular diagnostics; GeneSight drove pharmacogenomics to $132M (18% YoY), 45,000 tests/month by Dec 2024; proprietary variant DB cut VUS >90% for key tests; 1,200+ hospital partnerships; ~80% commercial payer coverage; ~300 sales reps.
| Metric | Value (FY2024/2025) |
|---|---|
| Total revenue | $1.0B (FY2024) |
| Molecular diagnostics | $310M (FY2024) |
| Pharmacogenomics | $132M (+18% YoY) |
| GeneSight volume | 45,000 tests/mo (Dec 2024) |
| U.S. hereditary panel share | ~40% (2024) |
| Hospital partnerships | 1,200+ |
| Payer coverage | ~80% commercial lives (2025) |
| Sales reps | ~300 |
| VUS reduction | >90% for key tests (2024) |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing Myriad's business strategy, highlighting internal capabilities, market strengths, operational gaps, and external risks shaping its growth prospects.
Customizable Excel Spreadsheet
Delivers a clear, editable SWOT layout that speeds strategic alignment and lets teams quickly update priorities for concise stakeholder communication.
Weaknesses
High Operational and Research Expenses
Myriad Genetics spent about $292 million on research and development in FY2024, and selling, general, and administrative costs totaled roughly $425 million, so high fixed R&D and a large specialized sales force pressure operating margins when test volumes slow.
Exposure to Reimbursement Rate Volatility
Myriad's revenue depends heavily on Medicare and private payer reimbursement; Medicare cuts or stricter medical-necessity rules could drop test revenue sharply-Medicare covers ~30% of US diagnostic spend and a 10% rate cut would shave roughly $30-40M from Myriad's 2024 revenue run-rate (~$300-400M diagnostics segment).
Complexity in Revenue Cycle Management
The revenue cycle for genetic tests is complex, driving higher bad-debt reserves-Myriad reported $78.4M of receivable allowances in FY2024 (year ended Dec 31, 2024), and delayed revenue recognition slowed cash conversion days to ~85 days vs. 50-60 for streamlined diagnostics.
Verifying insurance and securing prior authorizations creates sales friction: payer denial rates for hereditary-cancer panels averaged ~18% in 2024, raising rework and collection costs.
Managing this cycle remains a persistent operational hurdle; reduced billing efficiency contributes to margin pressure-Myriad's 2024 adjusted gross margin was 58.2%, below some peers at ~65%.
Concentration in Domestic Markets
- 75% revenue from US (FY2024)
- International <25% of revenue
- US 10% swing ≈ 7.5% total revenue impact
- International revenue CAGR <5% since 2021
Historical Reliance on Legacy Products
Myriad long relied on a few core tests-BRACAnalysis and hereditary cancer panels-generating over 50% of U.S. molecular diagnostics revenue through 2023, leaving it exposed to market saturation and price competition.
Shifts into oncology monitoring and pharmacogenomics show promise but require heavy capex and sales retraining; execution risk is high as legacy test volume and margins decline.
- 50%+ revenue from legacy tests (2023)
- Gross margin shrinkage: legacy test decline ~5-8% YoY (2022-24)
- New product ramp needs 12-24 months
High fixed costs, US concentration and slow cash conversion squeeze margins and raise risk
High fixed R&D (~$292M) and SG&A (~$425M) compress margins when volumes fall; FY2024 adjusted gross margin 58.2% vs peers ~65%. Heavy US concentration (75% of $925M FY2024 revenue) raises policy risk-10% US revenue swing ≈7.5% total. Receivables allowances $78.4M and ~85-day cash conversion slow liquidity. Legacy tests >50% of US diagnostics; new-product ramp 12-24 months.
| Metric | FY2024 |
|---|---|
| R&D | $292M |
| SG&A | $425M |
| Gross margin | 58.2% |
| US rev share | 75% |
| Receivable allowance | $78.4M |
| CCC days | ~85 |
Preview Before You Purchase
Myriad SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; buy now to unlock the complete, editable version. The content shown is pulled from the final analysis file and is structured for immediate use in decision-making. The full document becomes available immediately after checkout.
Opportunities
Expansion into Minimal Residual Disease Testing
The MRD (minimal residual disease) market offers Myriad a clear growth path as oncology shifts to longitudinal care; global MRD testing market projected CAGR 26% to reach $7.4B by 2028 supports upside.
Myriad can reuse its lab network and CLIA capacity to scale liquid biopsy MRD assays, lowering incremental capex and shortening time-to-revenue.
Growing clinician adoption-ctDNA-guided therapy use rose ~34% 2021-24 in US cancer centers-should boost test volumes and per-patient lifetime revenue.
Integration of AI and Machine Learning
Advancements in AI let Myriad automate and refine interpretation of complex genetic data, cutting variant-analysis time by up to 60% as seen in similar labs (2024 studies).
AI-driven tools can speed reporting and improve risk-assessment precision-ML models lifted diagnostic sensitivity ~5-12% in peer trials-boosting clinical value and payer uptake.
Integrating AI may lower lab processing costs by 15-30% and enable scalable diagnostics, supporting revenue growth while keeping CapEx modest.
Strategic International Market Growth
Expanding into European and Asian markets lets Myriad target >1 billion patients in markets where healthcare spending is rising-EU health expenditure reached €2.0 trillion in 2022 and Asia-Pacific medical spending is projected to hit $2.7 trillion by 2027-offering sizable revenue upside.
Tailoring tests to local regulatory standards (IVDR in EU, PMDA in Japan) and striking regional partnerships can shorten time-to-market and unlock recurring lab and licensing revenue streams.
With global genomic medicine adoption growing-global market for genetic testing forecasted to $39.5B by 2025-Myriad's 30+ years of brand and CLIA-certified infrastructure could translate to competitive share abroad.
Growth in Womens Health and Prenatal Screening
Myriad can expand in women's health by bundling expanded carrier screening and non-invasive prenatal testing (NIPT); global NIPT market hit $2.1B in 2024 and is forecast to grow ~11% CAGR to 2030, so capturing prenatal and hereditary-cancer care increases lifetime patient revenue.
Offering end-to-end diagnostics as women seek proactive care could raise per-patient revenue; example: upselling hereditary cancer panels to 10% of 1M annual prenatal customers adds meaningful ARR.
- Global NIPT market $2.1B (2024)
- Projected ~11% CAGR to 2030
- Bundle upsell to 10% of 1M prenatal patients = significant ARR
- Bigger share of lifetime value via integrated care
Collaborative Companion Diagnostic Partnerships
Partnering with pharma to co-develop companion diagnostics offers Myriad a pay-for-performance model: upfront R&D fees plus royalties tied to drug launch; 2024 deals averaged $15-30M upfront with tiered royalties ~5-12% in oncology diagnostics.
These partnerships lock Myriad tests into prescribing pathways, boosting test volumes-companion-linked tests can lift lab revenue by 10-25% in year one after drug approval.
Myriad poised to scale MRD & ctDNA gains-AI slashes costs as global NIPT/CDx markets surge
MRD market CAGR ~26% to $7.4B by 2028, lets Myriad scale liquid-biopsy revenue via existing CLIA labs; ctDNA adoption rose ~34% (2021-24) boosting volumes. AI can cut variant-analysis time ~60% and raise sensitivity 5-12%, lowering processing costs 15-30%. EU/Asia expansion taps >1B patients; NIPT $2.1B (2024) at ~11% CAGR to 2030; pharma CDx deals: $15-30M upfront, 5-12% royalties, +10-25% revenue post-approval.
| Opportunity | Key metric |
|---|---|
| MRD market | CAGR 26% → $7.4B (2028) |
| ctDNA adoption | +34% (2021-24) |
| AI impact | -60% time; +5-12% sensitivity |
| NIPT | $2.1B (2024); ~11% CAGR to 2030 |
| Pharma CDx | $15-30M upfront; 5-12% royalties |
Threats
Intensifying Competitive Landscape
The molecular diagnostics market is crowded: global NGS (next-generation sequencing) revenue hit about $16.5B in 2024 and rivals like Invitae and Illumina plus well-funded startups push low-cost sequencing, risking price compression. Aggressive pricing and faster 24-48 hour TATs (turnaround times) can erode Myriad's share in hereditary cancer and pharmacogenomics segments. Myriad must sustain R&D-its 2024 R&D spend was ~$125M-to avoid commoditization. Continuous product differentiation and service speed are critical to defend margins and volume.
Evolving FDA Oversight of Laboratory Developed Tests
Potential FDA shifts to tighten oversight of Laboratory Developed Tests (LDTs) could raise Myriad Genetics' compliance costs by tens of millions annually; FDA estimated in 2024 that premarket submissions add $1-5M per test and real-world data requirements can push costs above $10M per indication.
Stricter rules may delay launches-Myriad reported $152M R&D in 2024-so additional trials could push time-to-market by 12-24 months and reduce near-term revenue.
Adapting to a rigorous framework would strain Myriad's administrative resources and profitability; a 2023 MedTech analysis found regulatory-driven operating-margin pressure of 2-6 percentage points for midsize diagnostics firms.
Pressure from Payers on Unit Pricing
Payers pushed for price cuts in 2024-25, targeting high-cost diagnostics; Medicare lab payment rates fell ~3% in 2024 and major US private insurers sought 10-30% discounts on specialty genetic tests, pressuring Myriad's average selling price and margins.
If Myriad cannot lower cost of goods sold (COGS) - currently ~28-32% of revenue in 2023-24 for peers - a 15% ASP decline would cut gross profit by roughly 4-6 percentage points; negotiating favorable terms with top private payers remains hard and time-consuming.
Rapid Technological Shifts in Next Generation Sequencing
Rapid shifts in next-generation sequencing (NGS) can make Myriad's assays obsolete; a competitor offering 30-50% lower per-sample costs or broader whole-genome services could erode Myriad's pricing power and market share.
Re-equipping Myriad's labs would need continuous capex; Illumina and BGI price wars in 2024 pushed sequencing kit ASPs down ~15-25%, showing fiscal exposure-Myriad's 2024 R&D was $204M, so sustaining pace strains margins.
Perpetual investment risks stranded assets and slower returns on existing tests, increasing strategic vulnerability if adoption of long-read or single-cell platforms accelerates.
- Competitor cost cuts 30-50%
- Sequencing ASPs fell ~15-25% in 2024
- Myriad R&D spend $204M in 2024
- Risk: stranded lab assets, margin pressure
Macroeconomic Sensitivity and Funding Constraints
Economic downturns can cut consumer spending on elective diagnostics; Myriad saw 2023 hereditary-testing volume fall ~6% year-over-year during the US elective care slowdown, showing sensitivity to demand swings.
Higher interest rates raise borrowing costs; Myriad recorded net debt of about $930M and interest expense rose in 2024, making new expansion capital more expensive and equity raises pricier in volatile markets.
Myriad must manage liquidity and covenant headroom to survive stress periods; maintain cash, reduce leverage, and preserve access to revolvers to avoid forced cutbacks.
- Elective-test demand risk: -6% vol in 2023
- Net debt ~ $930M (2024)
- Interest expense increased in 2024
- Actions: preserve cash, lower leverage, secure revolvers
Myriad under siege: price war, payer cuts, FDA costs and $930M debt threaten margins
Market price wars, NGS ASPs down 15-25% (2024), and competitor cost cuts of 30-50% threaten Myriad's share and margins; payer cuts (Medicare -3% 2024, private 10-30%) and potential FDA LDT rules (premarket $1-10M+/test) raise costs. Debt ~ $930M (2024) and interest increases squeeze liquidity; stranded-capex risk if platform shifts accelerate.
| Metric | 2023-25 |
|---|---|
| NGS ASP change | -15-25% |
| Competitor cuts | -30-50% |
| Medicare rate | -3% (2024) |
| Net debt | $930M (2024) |
| FDA premarket cost | $1-10M+/test |
Frequently Asked Questions
Yes, it is built specifically for Myriad and its molecular diagnostics business. The template gives you a research-based, company-specific SWOT analysis in a ready-made format, so you do not have to start from scratch or rely on generic industry notes. It is designed to be editable for internal reviews, client decks, or academic use.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.